Overview of sotrastaurin clinical pharmacokinetics

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 540-543

  Kovarik, John M ^a   Slade, Alan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

pharmacokinetics; protein kinase C; Sotrastaurin

Indexed keywords

CD69 ANTIGEN; CYTOCHROME P450 3A4; DRUG METABOLITE; EVEROLIMUS; KETOCONAZOLE; MYCOPHENOLIC ACID; PROTEIN KINASE C; SOTRASTAURIN; TACROLIMUS; THYMIDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; FOOD; FOOD DRUG INTERACTION; HALF LIFE TIME; HUMAN; KIDNEY GRAFT; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REVIEW; STEADY STATE; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; DRUG INTERACTIONS; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; T-LYMPHOCYTES;

EID: 77957279278     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ee9e26     Document Type: Review

References (16)

1. Chaudhary D, Kasaian M. PKCtheta: a potential therapeutic target for T-cell-mediated diseases. Curr Opin Investig Drugs. 2006;7:432-437.
2. Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol. 2004;5:785-790.
3. Monks CR, Kupfer H, Tamir I, et al. Selective modulation of protein kinase C-theta during T-cell activation. Nature. 1997;385:83-86.
4. Bauer B, Krumböck N, Ghaffari-Tabrizi N, et al. T cell expressed PKCtheta demonstrates cell-type selective function. Eur J Immunol. 2000; 30:3645-3654.
5. Pfeifhofer C, Gruber T, Letschka T, et al. Defective IgG2a/2b class switching in PKC alpha-/- mice. J Immunol. 2006;176:6004-6011.
6. Mecklenbrauker I, Saijo K, Zheng NY, et al. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature. 2002;416:860-865.
7. Wagner J, van Matt P, Sedrani R, et al. Discovery of 3-(1H-indol-3-yl)-4- [2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem. 2009;52:6193-6196.
8. Skvara H, Dawid M, Kleyn CE, et al. Potential therapeutic option for psoriasis with AEB071, a novel protein kinase C inhibitor. J Clin Invest. 2008;118:3151-3159.
9. Slade A, Kovarik JM, Stitah S, et al. Effect of cyclosporine on AEB071 pharmacokinetics and lymphocyte pharmacodynamics [Abstract]. Am J Transplant. 2009;9(Suppl 2):408.
10. Slade A, Kovarik JM, Huang A, et al. AEB071 pharmacokinetics: effect of metabolic inhibition with ketoconazole [Abstract]. Am J Transplant. 2008;8(Suppl 2):513.
11. Slade A, Bartlett M, van Marle S, et al. AEB071 pharmacokinetics: combination with everolimus does not result in clinically relevant interaction [Abstract]. Transplantation. 2006;82(Suppl 2):865-866.
12. Kovarik JM, Steiger U, Grinyo JM, et al. Tacrolimus pharmacokinetics when combined with the protein kinase C inhibitor AEB071 in de novo kidney transplant patients [Abstract]. Am J Transplant. 2009; 9(Suppl 2):323.
13. Budde K, Sommerer C, Becker T, et al. AEB071, a novel protein kinase C-inhibitor: first clinical results of an AEB071 plus tacrolimus regimen in renal transplant recipients [Abstract]. Am J Transplant. 2009;9(Suppl 2):304.
14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
15. Kovarik JM, Steiger U, Grinyo JM, et al. Pharmacokinetics and exposure- efficacy relationships of the protein kinase C inhibitor AEB071 in de novo kidney transplant patients [Abstract]. Am J Transplant. 2009; 9(Suppl 2):409.
16. Friman S, Arns W, Banas B, et al. AEB071, a novel protein kinase Cinhibitor: evaluation of an AEB071 plus mycophenolate regimen in renal transplant recipients [Abstract]. Am J Transplant. 2009;9(Suppl 2): 323-333.